Pharmacokinetics and pharmacodynamics of dexamethasone after intravenous administration in camels: Effect of dose

Veterinary Research Communications

Volumn 28, Issue 6, 2004, Pages 525-542

  Al Katheeri, N A ^a   Wasfi, I A ^a   Lambert, M ^b   Saeed, A ^c  

^a Camelracing Laboratory   (United Arab Emirates)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c Veterinary Research Centre   (United Arab Emirates)

Author keywords

Camels; Clearance; Dexamethasone; Doses; Pharmacodynamics; Pharmacokinetics; Racing

Indexed keywords

BIOLOGICAL MARKER; DEXAMETHASONE SODIUM PHOSPHATE; DEXOL 5; GLUCOSE; HYDROCORTISONE; METHYLPREDNISOLONE;

ANIMAL EXPERIMENT; ARTICLE; BOLUS INJECTION; CAMEL; COMPARTMENT MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; FEMALE; GLUCOSE BLOOD LEVEL; HYDROCORTISONE BLOOD LEVEL; IC 50; LINEAR SYSTEM; LOW DRUG DOSE; LYMPHOCYTE COUNT; NEUTROPHIL; NONHUMAN; PHARMACODYNAMICS; RADIOIMMUNOASSAY; SINGLE DRUG DOSE; STEADY STATE;

ANIMALS; BLOOD GLUCOSE; CAMELS; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HYDROCORTISONE; INJECTIONS, INTRAVENOUS; LYMPHOCYTES; NEUTROPHILS; PROTEIN BINDING; REGRESSION ANALYSIS;

CAMELIDAE;

EID: 3042536926     PISSN: 01657380     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:VERC.0000040243.30199.1f     Document Type: Article

References (62)

1. Abdulla, O.M., Wasfi, I.A. and Gadir, F.A., 1988. The Arabian race camel normal parameters: haemograms enzymes and minerals. Comparative Biochemistry and Physiology, 90, 237-239
2. Abrams, K. and Brooks, D.E., 1990. Equine recurrent uveitis: current concepts in diagosis and treatment. Equine Practice, 12, 27-35
3. Adam, P.A.J. and Hyanes, R.C. Jr., 1969. Control of hepatic mitochondrial CO2 fixation by glucagons, epinephrine and cortisol. Journal of Biochemistry and Chemistry, 244, 6444-6450
4. Akaike, H., 1976. An information criteria (AIC). Mathematical Science, 14, 5-9
5. Armbruster, D.A., Tillman, H.D. and Hubbs, L.M., 1994. Limit of detection (LOD)/limit of quantitation (LOQ): comparison of the empirical and the statistical methods exemplified with GC/MS assays of abused drugs. Clinical Chemistry, 40, 1233-1238
6. Braat, M.C.P., Oosterhuis, B., Koopmans, R.P., Meewis, J.M. and VanBoxtel, C.J., 1992. Kinetic-dynamic modelling of lymphocytopenia induced by the combined action of dexamethasone and hydrocortisone in humans, after inhalation and intravenous administration of dexamethasone. Journal of Pharmacology and Experimental Therapeutics, 262, 509-515
7. Brady, M.E., Sartiano, G.P. Rosenblum, S.L. Zaglam, N.E. and Bauguess, C.T., 1986. The pharmacokinetics of single high doses of dexamethasone in cancer patients. European Journal of Clinical Pharmacology, 32, 593-596
8. Chen, C.L., Zhu, D., Gillis, K.D. and Meleka-Boules, M., 1996. Use of enzyme-linked immunosorbent assay and radioimmunoassay to determine serum and urine dexamethasone concentration in Thoroughbreds after intravenous administration of the steroid. American Journal of Veterinary Research, 57, 182-186
9. Cross, R.S.N., 1966. Equine periodic ophthalmia. Veterinary Record, 78, 8-13
10. Cunningham, F.E., Rogers, S., Fischer, J.H. and Jensen, R.C., 1996. The pharmacokinetics of dexamethasone in the Thoroughbred racehorse. Journal of Veterinary Pharmacology and Therapeutics, 19, 68-71
11. Dayneka, N.L., Garg, V. and Jusko, W.J., 1993. Comparison of four basic models of indirect pharmacodynamic responses. Journal of Pharmacokinetics and Biopharmaceutics, 21, 457-478
12. Eiler, H. and Oliver, J., 1980. Combined dexamethasone suppression and cosyntropin (synthetic ACTH) stimulation test in the dog: new approach to testing adrenal gland function. American Journal of Veterinary Research, 41, 1243-1246
13. Eiler, H., 1986. The combined dexamethsaone suppression/ACTH stimulation test: test principle and diagnostic value in the adrenopathic dog. California Veterinary, 10-15
14. Ferguson, D.C. and Hoenig, M., 1995. Glucocorticoids, mineralocorticoids, and steroid synthesis inhibitors. In H.R. Adams (ed.), Veterinary Pharmacology and Therapeutics, 7th ed. (Iowa State University Press, Ames, IA), 622-643
15. Fisher, E.L., Ludwig, E.A. and Jusko, W.J., 1992. Pharmacoimmunodynamics of methylprednisolone: trafficking of helper T lymphocytes. Journal of Pharmacokinetics and Biopharmaceutics, 20, 319-331
16. Friederich, A., Schulz, R. and Meyer, H.H.D., 1992. Use of enzyme immunoassay and reverse-phase high-performance liquid chromatography to detect and confirm identity of dexamethasone in equine blood. American Journal of Veterinary Research, 53, 2213-2220
17. Gibaldi, M. and Perrier, D., 1982. Pharmacokinetics, (Marcel Dekker, New York), 45-108
18. Greco, D.S., Braun, S.A., Gauze, J.J., Weise, D.W. and Buck, J.M., 1993. Dexamethasone pharmacokinetics in clinically normal dogs during low- and high-dose dexamethasone suppression testing. American Journal of Veterinary Research, 54, 580-585
19. Grundy, S.A. and Barton, C., 2001. Influence of drug treatment on survival of dogs with immune-mediated haemolytic amenia: 88 cases (1989-1999). Journal of Veterinary and Medical Association, 218, 543-546
20. Gupta, S.K., Ritchie, J.C. Ellinwood, E.H., Wiedemann, K. and Holsboer, F., 1992. Modeling the pharmacokinetics and pharmacodynamics of dexamethasone in depressed patients. European Journal of Clinical Pharmacology, 43, 51-55
21. Hare, E.L., Yeh, K.C., Ditzler, C.A., McMahon, F.G., Duggan, D.E., 1975. Bioavailability of dexamethasone. II. Dexamethasone phosphate. Clinical Pharmacology and Therapeutics, 18, 330-337
22. Hochhaus, G., Barth, J., Al-Fayoumi, S., Suarez, S., Derendrof, H., Hochhaus, R. and Möllmann, H., 2001. Pharmacokinetics and pharmacodynamics of dexamethasone sodium-m-sulfobenzoate (DS) after intravenous and intramuscular administration: a comparison with dexamethasone phosphate (DP). Journal of Clinical Pharmacology, 41, 425-434
23. Jones, T.D.C., 1942. Equine periodic ophthalmia. American Journal of Veterinary Research, 3, 45-71
24. Jusko, W.J. and Ko, H.C., 1994. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clinical Pharmacology and Therapuetics, 56, 406-419
25. Kemppainen, R.J. and Peterson, M.E., 1993. Circulating concentration of dexamethasone in healthy dogs, dogs with hyperadrenocorticism, and dogs with nonadrenal illness during dexamethasone suppression testing. American Journal of Veterinary Research, 54, 1765-1769
26. King, J.N., 1994. Correlation between the pharmacokinetics of oxidanac and inhibition of thromboxane B2 in calves. Journal of Veterinary Pharmacology and Therapeutics, 17, 193-201
27. Landoni, M.F. and Lees P., 1995. Comparison of the anti-inflammatory actions of flunixin and ketoprofen in horses applying PK/PD modeling. Equine Veterinary Journal, 27, 247-256
28. Landoni, M.F., Cunningham, F.M. and Lees P., 1995. Determination of pharmacokinetics and pharmacodynamics of flunixin in calves by use of pharmacokinetic/pharmacodynamic modelling. American Journal of Veterinary Research, 56, 786-794
29. Landoni, M.F., Cunningham, F.M. and Lees P., 1996. Pharmacokinetics and pharmacodynamics of tolfenamic acid in calves. Research in Veterinary Science, 61, 26-32
30. Lane, P.J., Lees, P., and Fink-Gremmels, J., 1990. Action of dexamethasone in an equine model of acute non-immune inflammation. Research in Veterinary Science, 48, 87-95
31. Long, C.N.H., Katzin, B. and Fry, E.G., 1940. Adrenal cortex and carbohydrate metabolism. Endocrinology, 26, 309-344
32. Magee, M.H., Blum, R.A., Lates, C.D. and Jusko, W.J., 2001. Prednisolone pharmacokinetics and pharmacodynamics in relation to sex and race. Journal of Clinical Pharmacology, 41, 1180-1194
33. Meibohm, B., Derendorf, H., Möllmann, H., Fröhlich, P., Tromm, A., Wagner, M., Homrighausen, S., Krieg, M. and Hochhaus, G., 1999. Mechanism-based PK/PD model for the lymphocytopenia induced by endogenous and exogenous c-376
34. Milad, M.A., Ludwig, E.A., Anne, S., Middleton, J.R.E. and Jusko, W.J., 1994. Pharmacodynamic model for joint exogenous and endogenous corticosteroid suppression of lymphocyte trafficking. Journal of Pharmacokinetics and Biopharmaceutics, 22, 469-479
35. Möllmann, H., Hochhaus, G., Rohatagi, S., Barth, J. and Derendrof, H., 1995. Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone. Pharmacology Research, 12, 1096-1100
36. Möllmann, H., Hochhaus, G., Rohatagi, S., Barth, J., Derendrof, H., Krieg, M., Weisser, H. and Möllmann, A.C., 1996. Pharmacokinetics and pharmacodynamics of cloprednol. International Journal of Clinical Pharmacology and Therapeutics, 34, 1-5
37. Möllmann, H., Wagner, M., Meibohm, B., Hochhaus, G., Barth, J., Stöckmann, R., Krieg, M., Weisser, H., Falcoz, C. and Derendorf, H., 1998. Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. European Journal of Clinical Pharmacology, 53, 459-467
38. Nugent, C.A., Nichols, T. and Tyler, F., 1965. Diagnosis of Cushing's syndrome. Archives of International Medicine, 116, 172-176
39. Oosterhuis, B., TenBerge, R.J.M., Sauerwein, H.P., Endert, E., Schellenkens, P.T.A. and VanBoxtel, C.J., 1983. Pharmacokinetic-pharmacodynamic modeling of prednisolone induced lymphocytopenia in man. Journal of Experimental Therapeutics, 229, 539-546
40. Pugh, D.M., 1991. The trophic hormones and the endocrine regulators of metabolism. In: C.G. Brander, D.M. Pugh and R.J. Bywater, et al. (eds), Veterinary Applied Pharmacology and Therapeutics, 5th ed., (Baillière Tindall, London), 259-278
41. Qiao, G.L. and Fung, F., 1994. Pharmacokinetic-pharmacodynamic modeling of meperidine in goats (II): modeling. Journal of Veterinary Pharmacology and Therapeutics, 17, 127-134
42. Rohatagi, S. Soeldener, A., Barth, J., Möllmann, H., Hochhaus, G. and Derendorf, H., 1994. Pharmacokinetic and pharmacodynamic modelling of oral multiple dosing of methylprednisolone. Pharmaceutical Research, 11, S369
43. Rohatagi, S. Hochhaus, G., Möllmann, H., Barth, J., Galia, E., Erdmann, M., Sourgens, H. and Derendorf, H., 1995. Pharmacokinetic and pharmacodynamic evaluation of triamcinolone acetonide after intravenous oral and inhaled administration. Journal of Clinical Pharmacology, 35, 1187-1193
44. Rohdewald, P., Möllmann, H., Barth, J., Rehder, J. and Derendorf, H., 1987. Pharmacokinetics of dexamethasone and its phosphate ester. Biopharmaceutics and Drug Disposition, 8, 205-212
45. Schalm O.W., 1965. Veterinary Haematology, (Baillière Tindall, London)
46. Schwarz, G., 1978. Estimating the dimension of a model. Analytical Statistics, 6, 461-464
47. Sheiner, L.B., Stanki, D.R., Vozeh, S., Miller, R.D. and Ham, J., 1979. Simultaneous modeling of pharmacokinetics and pharmacodynamic: application to d-tubocurarine. Clinical Pharmacology and Therapeutics, 25, 358-371
48. Spiess, B.M., Nyikos, S., Stummer, E. Sabin, A. and Naegeli, H., 1999. Systemic dexamethasone concentration in horses after continued topical treatment with an ophthalmic preparation of dexamethasone. American Journal of Veterinary Research, 60, 571-576
49. Toutain, P.L., 2002. Pharmacokinetic/pharmacodynamic integration in drug development and dosage-regimen optimization for veterinary medicine. American Association of Pharmaceutical Scientist, Pharmaceutical Science, 4, 38 (http://www.aapspharmsci.org/scientificjournals/ pharmsci/journal/ps040438.htm)
50. Toutain, P.L., Brandon, R.A., Alvinerie M, Garcia-Villar, R. and Ruckebusch, Y., 1982. Dexamethasone in cattle: pharmacokinetics and action on the adrenal gland. Journal of Veterinary Pharmacology and Therapeutics, 5, 33-43
51. Toutain, P.L., Alvinerie, M. and Ruckebusch, Y., 1983. Pharmacokinetics of dexamethasone and its effect on adrenal gland function in the dog. American Journal of Veterinary Research, 44, 212-217
52. Toutain P.L., Brandon R.A., de Pomyers H. Alvinerie, M. and Baggot J.D., 1984. Dexamethasone and prednisolone in the horse: pharmacokinetics and action on the adrenal gland. American Journal of Veterinary Research, 45, 1750-1756
53. Toutain, P.L., Autefage, A., Legrand, C. and Alvinerie, M., 1994. Plasma concentrations and therapeutic efficacy of phenylbutazone and flunixin meglumine in the horse: pharmacokinetic/pharmacodynamic modelling. Journal of Veterinary Pharmacology and Therapeutics, 17, 459-469
54. Toutain, P.L., Cester, C.C., Haak, T. and Laroute, V., 2001. A pharmacokinetic/pharmacodynamic approach vs. a dose titration for the dtermination of a dosage regimen: the case of nimesulide, a Cox-2 selective nonsteroidal anti-inflammatory drug in the dog. Journal of Veterinary Pharmacology and Therapeutics, 24, 43-55
55. Tsuei, S.E., Moore, R.G., Ashley, J.J. and McBride, W.G., 1979. Disposition of synthetic glucocorticoids. I. Pharmacokinetics of dexamethasone in healthy adults. Journal of Pharmacology and Biopharmaceutics, 7, 249-264
56. Wald, J.A., Salazar, D.E., Cheng, H. and Jusko, W.J., 1991. Two-compartment basophil cell trafficking model for methylprednisolone pharmacodynamics. Journal of Pharmacokinetic and Biopharmaceutics, 19, 521-536
57. Wald, J.A., Law, R.M., Luawig, E.A., Sloan, R.R., Middleton, E. Jr., and Jusko, W.J., 1992. Evaluation of dose-related pharmacokinetics and pharmacodynamics of prednisolone in man. Journal of Pharmacokinetics and Biopharmacuietics, 20, 567-589
58. Wasfi, I.A., Gadir, F.A. and Abdulla, O.M., 1989. The acute effects of dexamethasone on some haematological parameters and serum biochemistry in the camel (Camelus dromedarius). Revue d'Élévage et de. Médecine Vétérinaire des Pays Tropicaux, 42, 479-483
59. Wasfi, I.A., Boni, N.S., Elghazali, M., Abdel Hadi, A.A., Almuhrami, A.M., Barezaig, I.M. and Al Katheeri, N.A., 2000. The pharmacokinetics, metabolism and urinary detection of caffeine in camels. Research in Veterinary Science, 69, 69-74
60. Wilson, R.T., 1984. The Camel, (The Print House, Singapore)
61. Workman, R.J., Vaughn, W.K. and Stone, W.J., 1986. Dexamethasone suppression testing in chronic renal failure: pharmacokinetics of dexamethasone and demonstration of a normal hypothalamic-pituitary-adrenal axis. Journal Clinical Endocrinology and Metabolism, 63, 741-746
62. Young, M.C., Cook N., Read G.F. and Hughes, I.A., 1989. The pharmacokinetics of low-dose dexamethasone in congenital adrenal hyperplasia. European Journal of Clinical Pharmacology, 37, 75-77